期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
全身麻醉联合硬化阻滞麻醉对合并糖尿病手术患者术后感染与血流动力学的影响 被引量:3
1
作者 李瑞峰 《现代诊断与治疗》 CAS 2021年第14期2295-2297,共3页
目的探究糖尿病手术患者应用全身麻醉联合硬化阻滞麻醉,对术后血流动力学和感染的影响。方法选取2019年3月~2020年3月我院收治的95例合并糖尿病手术患者,随机分为对照组47例和观察组48例。对照组应用全麻,观察组在全麻基础上联合实施硬... 目的探究糖尿病手术患者应用全身麻醉联合硬化阻滞麻醉,对术后血流动力学和感染的影响。方法选取2019年3月~2020年3月我院收治的95例合并糖尿病手术患者,随机分为对照组47例和观察组48例。对照组应用全麻,观察组在全麻基础上联合实施硬膜外阻滞麻醉,对比两组患者术后感染发生率及麻醉方案对血流动力学的影响。结果观察组和对照组术后感染发生率分别为4.17%、17.02%,观察组术后感染率相比更低(P<0.05);两组手术结束即时血流动力学指标无明显差异(P>0.05),观察组术后6h、24h、48h时间点患者血流动力学指标和对照组比较更加稳定(P<0.05)。结论糖尿病手术患者选择全身麻醉联合硬化阻滞麻醉方案效果理想,血流动力学稳定且不会增加应激反应,有助于降低术后感染发生率,可显著提升手术安全性,值得推广及应用。 展开更多
关键词 全身麻醉 硬化阻滞麻醉 糖尿病 血流动力学
下载PDF
全身麻醉联合硬化阻滞麻醉对糖尿病手术患者术后感染与血流动力学的影响 被引量:3
2
作者 曹艳 王军 蒋敢 《血栓与止血学》 2020年第1期76-77,79,共3页
目的观察全身麻醉联合硬化阻滞麻醉对糖尿病手术患者术后感染与血流动力学的影响。方法选取2018年5月至2019年5月医院收治的需要进行糖尿病手术患者共120例作为研究对象,根据患者麻醉方式不同将其分为对照组与实验组,其中对照组60例给... 目的观察全身麻醉联合硬化阻滞麻醉对糖尿病手术患者术后感染与血流动力学的影响。方法选取2018年5月至2019年5月医院收治的需要进行糖尿病手术患者共120例作为研究对象,根据患者麻醉方式不同将其分为对照组与实验组,其中对照组60例给予全身麻醉,实验组60例给予全身麻醉联合硬化阻滞进行手术,对比两组患者术后感染与血流动力学的变化情况。结果实验组患者在手术后6 h、12 h、24 h、48 h、72 h感染率明显低于对照组(P<0.05)。实验组与对照组在手术刚完成时将HR、MAP、SBP、DBP血流动力学指标进行对比无统计学差异(P>0.05),在术后T2~T4时间段实验组的血流动力学指标(HR、MAP、SBP、DBP)较对照组更稳定,具有统计学差异(P<0.05)。结论全身麻醉联合硬化阻滞麻醉方式相对于全身麻醉方式,可有效改善术后感染情况,使患者的血流动力学指标更加稳定。 展开更多
关键词 全身麻醉 硬化阻滞 术后感染 血流动力学
下载PDF
拉西地平、氨氯地平对人脐静脉内皮细胞间粘附分子1表达的影响 被引量:7
3
作者 刘海宁 张兴华 耿庆信 《中国动脉硬化杂志》 CAS CSCD 2005年第5期575-578,共4页
目的观察第三代二氢吡啶类钙通道阻滞剂拉西地平、氨氯地平对肿瘤坏死因子a诱导的人脐静脉内皮细胞间粘附分子1表达的影响,以探讨拉西地平、氨氯地平抗动脉粥样硬化机制。方法体外培养人脐静脉内皮细胞,以低密度脂蛋白作为载体分别加入... 目的观察第三代二氢吡啶类钙通道阻滞剂拉西地平、氨氯地平对肿瘤坏死因子a诱导的人脐静脉内皮细胞间粘附分子1表达的影响,以探讨拉西地平、氨氯地平抗动脉粥样硬化机制。方法体外培养人脐静脉内皮细胞,以低密度脂蛋白作为载体分别加入不同浓度的拉西地平(5.26×10-5mmol/L、1.58×10-4mmol/L、3.16×10-4mmol/L)和氨氯地平(5.26×10-6mmol/L、1.58×10-5mmol/L、3.16×10-5mmol/L)共同孵育45 min,再加入肿瘤坏死因子a共同孵育6 h,采用流式细胞术和逆转录聚合酶链反应分别测定细胞间粘附分子1蛋白和mRNA的表达。结果不同浓度的拉西地平显著抑制细胞间粘附分子1的表达,随浓度增加,抑制作用逐渐增强;氨氯地平在低浓度时无明显抑制作用,但中、高浓度时可明显抑制细胞间粘附分子1的表达。流式细胞术和逆转录聚合酶链反应的检测结果基本一致。结论拉西地平和氨氯地平均能够显著抑制肿瘤坏死因子a诱导的细胞间粘附分子1表达,但拉西地平的抑制作用强于氨氯地平,可能与其不同的抗氧化活性有关。 展开更多
关键词 药理学 钙通道阻滞剂抗动脉粥样硬化作用 逆转录聚合酶链反应 肿瘤坏死因子A 人脐静脉内皮细胞 细胞间粘附分子1
下载PDF
Hypertension in the elderly: insights from recent research
4
作者 Jun-Hua Wang Shan Zhou 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2010年第2期116-125,共10页
Hypertension is a leading cause of mortality and morbidity around the world and,prevalence of hypertension is increasing with aging.Hypertension in the elderly is associated with increased occurrence rates of sodium s... Hypertension is a leading cause of mortality and morbidity around the world and,prevalence of hypertension is increasing with aging.Hypertension in the elderly is associated with increased occurrence rates of sodium sensitivity,isolated systolic hypertension,and 'white coat effect'.Arterial stiffness and endothelial dysfunction also increase with age.These factors should be considered in selecting antihypertensive therapy.The prime objective of this therapy is to prevent stroke.The fmdings of controlled trials show that there should be no cut-off age for treatment.A holistic program for controlling cardiovascular risks should be fully discussed with the patient,including evaluation to exclude underlying causes of secondary hypertension,and implementation of lifestyle measures.The choice of antihypertensive drug therapy is influenced by concomitant disease and previous medication history,but will typically include a thiazide diuretic as the first-line agent;to this will be added an angiotensin inhibitor and/or a calcium channel blocker.Beta blockers are not generally recommended,in part because they do not combat the effects of increased arterial stiffness.The hypertension-hypoten-sion syndrome requires case-specific management.Drug-resistant hypertension is important to differentiate from faulty compliance with medication.Patients resistant to the third-line drug therapy may benefit from treatment with extended-release isosorbide mononitrate.A trial of spironolactone may also be worthwhile. 展开更多
关键词 HYPERTENSION ELDERLY antihypertensive treatment patient management
下载PDF
Recent advances in the management of variceal bleeding 被引量:7
5
作者 Ihteshamul Haq Dhiraj Tripathi 《Gastroenterology Report》 SCIE EI 2017年第2期113-126,I0001,共15页
Acute haemorrhage from ruptured gastroesophageal varices is perhaps the most serious consequence of uncontrolled portal hypertension in cirrhotic patients.It represents a medical emergency and is associated with a hig... Acute haemorrhage from ruptured gastroesophageal varices is perhaps the most serious consequence of uncontrolled portal hypertension in cirrhotic patients.It represents a medical emergency and is associated with a high morbidity and mortality.In those who survive the initial bleeding event,the risks of further bleeding and other decompensated events remain high.The past 30 years have seen a slow evolution of management strategies that have greatly improved the chances of surviving a variceal haemorrhage.Liver cirrhosis is a multi-staged pathological process and we are moving away from a one-size-fits-all therapeutic approach.Instead there is an increasing recognition that a more nuanced approach will yield optimal survival for patients.This approach seeks to risk stratify patients according to their disease stage.The exact type and timing of treatment offered can then be varied to suit individual patients.At the same time,the toolbox of available therapy is expanding and there is a continual stream of emerging evidence to support the use of endoscopic and pharmacological therapies.In this review,we present a summary of the treatment options for a variety of different clinical scenarios and for when there is failure to control bleeding.We have conducted a detailed literature review and presented up-to-date evidence from either primary randomized-controlled trials or meta-analyses that support current treatment algorithms. 展开更多
关键词 VARICES acute varices haemorrhage CIRRHOSIS PROPHYLAXIS non-selective beta-blockers variceal band ligation
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部